OTC Markets OTCPK - Delayed Quote USD

Valneva SE (INRLF)

2.4800

+0.1800

+(7.83%)

At close: January 23 at 7:00:00 PM EST

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company exp

GlobeNewswire 4 days ago

INRLF
+7.83%
VALN
+7.02%
High Growth Tech Stocks To Watch In January 2025

As we enter January 2025, global markets are showing signs of optimism with cooling inflation and strong bank earnings driving U.S. stocks higher, while European markets benefit from slower-than-expected inflation potentially leading to rate cuts. In this environment, investors might look for high growth tech stocks that can capitalize on these favorable conditions by demonstrating robust innovation and adaptability in a rapidly evolving market landscape.

Simply Wall St. 4 days ago

STRYF

INRLF
+7.83%
VALN
+7.02%
Valneva announces positive outcomes from chikungunya vaccine trial

The trial demonstrated a ‘sustained’ sero-response rate of 98.3% one year post-vaccination.

Clinical Trials Arena 5 days ago

VLA.PA
-0.79%
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

Valneva reports positive data from its Phase 3 - VLA1553-321 study of the IXCHIQ vaccine.

Zacks 5 days ago

VLA.PA
-0.79%
RMD
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Saint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to thi

GlobeNewswire 6 days ago

INRLF
+7.83%
VALN
+7.02%
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Saint Herblain (France), January 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which

GlobeNewswire 20 days ago

INRLF
+7.83%
VALN
+7.02%
VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights December 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chang

GlobeNewswire 23 days ago

INRLF
+7.83%
VALN
+7.02%
Exploring High Growth Tech Stocks for December 2024

As global markets experience fluctuations, with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainty, the focus on high growth tech stocks becomes particularly relevant for investors seeking potential opportunities amidst broader market volatility. In such an environment, identifying a promising stock often involves looking at companies with innovative technologies and strong growth prospects that can navigate economic challenges and capitalize on...

Simply Wall St. last month

INRLF
+7.83%
VALN
+7.02%
Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia

Valneva ( (VALN) ) just unveiled an announcement. Valneva has entered into a significant collaboration with the Serum Institute of India (SII) to expand the reach of its single-shot chikungunya vaccine in Asia amidst a severe outbreak in India. This exclusive license agreement will allow broader access to the vaccine, particularly in low-and-middle-income countries, backed by a $41.3 million funding agreement with CEPI and the European Union. The partnership will involve a technology transfer fo

TipRanks last month

INRLF
+7.83%
VALN
+7.02%
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the

GlobeNewswire last month

INRLF
+7.83%
VALN
+7.02%
VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA Declaration of shares and voting rights November 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this ch

GlobeNewswire last month

INRLF
+7.83%
VALN
+7.02%
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal (BMJ), one of the world’s leading peer-reviewed medical journals. The article, titled, “The Global Health and Economic Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Bor

GlobeNewswire last month

INRLF
+7.83%
VALN
+7.02%
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this va

GlobeNewswire last month

INRLF
+7.83%
VALN
+7.02%
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.

Zacks last month

VLA.PA
-0.79%
GMED

HAE
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-y

GlobeNewswire last month

INRLF
+7.83%
VALN
+7.02%
High Growth Tech Stocks To Explore This November 2024

As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.

Simply Wall St. 2 months ago

STRYF

INRLF
+7.83%
VALN
+7.02%
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Shares in European vaccine makers tumbled after President-elect Donald Trump picked vaccine sceptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

The Wall Street Journal 2 months ago

INRLF
+7.83%
VALN
+7.02%
BVNKF
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacci

GlobeNewswire 2 months ago

INRLF
+7.83%
VALN
+7.02%
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cat

GlobeNewswire 2 months ago

INRLF
+7.83%
VALN
+7.02%
Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva SE (INRLF) reports a significant turnaround with increased sales and a positive operating profit, despite challenges in the US market.

GuruFocus.com 2 months ago

VLA.PA
-0.79%

Performance Overview

Return	INRLF	CAC 40
YTD	+18.66%	+8.40%
1-Year	-41.51%	+7.30%
3-Year	-85.98%	+12.15%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (INRLF)

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

High Growth Tech Stocks To Watch In January 2025

Valneva announces positive outcomes from chikungunya vaccine trial

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

VALNEVA Declaration of shares and voting rights: December 31, 2024

Exploring High Growth Tech Stocks for December 2024

Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

VALNEVA - Declaration of shares and voting rights: November 30, 2024

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

High Growth Tech Stocks To Explore This November 2024

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Performance Overview